WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317786
CAS#: 217087-09-7 (magnesium hydrate)
Description: Esomeprazole Magnesium is the magnesium salt of esomeprazole, the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulphenamide; the active sulphenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.
Hodoodo Cat#: H317786
Name: Esomeprazole Magnesium hydrate
CAS#: 217087-09-7 (magnesium hydrate)
Chemical Formula: C34H42MgN6O9S2
Exact Mass: 0.00
Molecular Weight: 767.170
Elemental Analysis: C, 53.23; H, 5.52; Mg, 3.17; N, 10.95; O, 18.77; S, 8.36
Related CAS #: 161796-78-7(sodium) 119141-88-7(free) 161973-10-0 (magnesium) 217087-09-7 (magnesium hydrate) 161796-84-5 (potassium) 914613-86-8 (strontium anhydrous)
Synonym: Esomeprazole Magnesium; Omeprazole magnesium; Nexium; H 168/68 magnesium; AstraZeneca Brand of Esomeprazole; Magnesium; Esomeprazole; Esomeprazole Magnesium; Esomeprazole Potassium; Esomeprazole Sodium; Esomeprazole Strontium; Esomeprazole Strontium Anhydrous; Nexium; Strontium, Esomeprazole;
IUPAC/Chemical Name: magnesium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide trihydrate
InChi Key: VEVZQDGATGBLIC-UHFFFAOYSA-N
InChi Code: InChI=1S/2C17H18N3O3S.Mg.3H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;;;/h2*5-8H,9H2,1-4H3;;3*1H2/q2*-1;+2;;;
SMILES Code: CC1=CN=C(CS(C2=NC3=C(C=CC(OC)=C3)[N-]2)=O)C(C)=C1OC.CC4=CN=C(CS(C5=NC6=C(C=CC(OC)=C6)[N-]5)=O)C(C)=C4OC.[H]O[H].[H]O[H].[H]O[H].[Mg+2]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H+, K+-ATPase inhibitor. |
| In vitro activity: | This study found that the expression of both DDAH and iNOS were significantly downregulated by esomeprazole (Fig. 1). For example, the gene expression of iNOS was increased by about 100-fold upon induction with bleomycin, and treatment with esomeprazole decreased the induction in iNOS expression by about 25-fold (Fig. 1). Reference: J Inflamm (Lond). 2021; 18: 17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136131/ |
| In vivo activity: | The administration of esomeprazole in different doses significantly reduced the MDA levels in the HE+WIR group (P=0.0001<0.001) and the LE+WIR group (P=0.0001<0.001) (Figure 4A; Table 3). Compared with the NS group, the level of GSH in the WIR group was declined (P=0.012<0.05), which was rescued by the high-dose esomeprazole treatment (P=0.036<0.05) (Figure 4B; Table 3). The assessment revealed that the WIR treatment significantly reduced the levels of SOD relative to that of the NS group (P=0.025<0.05), and this condition was reversed by the prophylactic administration of the high-dose esomeprazole (P=0.048<0.05) (Figure 4C; Table 3). The rats in the HE group did not show any significant changes in the levels of MDA (P=0.963), GSH (P=0.980), SOD (P=0.875) and SOD1 (P=0.809) in the stomach tissue compared with the NS group rats (Figure 4A–D). Reference: Drug Des Devel Ther. 2019; 13: 2969–2984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709796/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 50.0 | 65.17 |
The following data is based on the product molecular weight 767.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076. 3. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 4. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297. |
| In vitro protocol: | 1. Ebrahimpour A, Wang M, Li L, Jegga AG, Bonnen MD, Eissa NT, Raghu G, Jyothula S, Kheradmand F, Hanania NA, Rosas IO, Ghebre YT. Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. J Inflamm (Lond). 2021 May 19;18(1):17. doi: 10.1186/s12950-021-00284-6. PMID: 34011367; PMCID: PMC8136131. 2. Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett. 2020 Dec;20(6):329. doi: 10.3892/ol.2020.12193. Epub 2020 Oct 6. PMID: 33101498; PMCID: PMC7577076. |
| In vivo protocol: | 1. Xie W, Huang X, Chen R, Chen R, Li T, Wu W, Huang Z. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. PMID: 31686780; PMCID: PMC6709796. 2. Pham N, Ludwig MS, Wang M, Ebrahimpour A, Bonnen MD, Diwan AH, Kim SJ, Bryan J, Newton JM, Sikora AG, Donovan DT, Sandulache V, Ghebre YT. Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis. Radiat Res. 2019 Nov;192(5):473-482. doi: 10.1667/RR15398.1. Epub 2019 Aug 15. PMID: 31415221; PMCID: PMC6876297. |
1: Lotfy HM, Amer SM, Zaazaa HE, Mostafa NS. A comparative study of the novel spectrophotometric methods versus conventional ones for the simultaneous determination of Esomeprazole magnesium trihydrate and Naproxen in their binary mixture. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:538-46. doi: 10.1016/j.saa.2015.07.007. Epub 2015 Jul 3. PubMed PMID: 26162342.
2: Kan SL, Lu J, Liu JP, Zhao Y. Preparation and in vitro/in vivo evaluation of esomeprazole magnesium-modified release pellets. Drug Deliv. 2015 Jul 21:1-8. [Epub ahead of print] PubMed PMID: 24892629.
3: Kumar P, Ganure AL, Subudhi BB, Shukla S. Preparation and characterization of pH-sensitive methyl methacrylate-g-starch/hydroxypropylated starch hydrogels: in vitro and in vivo study on release of esomeprazole magnesium. Drug Deliv Transl Res. 2015 Jun;5(3):243-56. doi: 10.1007/s13346-015-0221-7. PubMed PMID: 25787732.
4: Liu Z, Wang W, Chen H, Liu J, Zhang W. Novel application method of talcum powder to prevent sticking tendency and modify release of esomeprazole magnesium enteric-coated pellets. Pharm Dev Technol. 2015 Feb 24:1-10. [Epub ahead of print] PubMed PMID: 25708151.
5: Choi Y, Han H, Shin D, Lim KS, Yu KS. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. Drug Des Devel Ther. 2015 Jul 31;9:4127-35. doi: 10.2147/DDDT.S86725. eCollection 2015. PubMed PMID: 26257511; PubMed Central PMCID: PMC4527374.
